These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 32716740)

  • 1. Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.
    You B; Bolze PA; Lotz JP; Massardier J; Gladieff L; Joly F; Hajri T; Maucort-Boulch D; Bin S; Rousset P; Devouassoux-Shisheboran M; Roux A; Alves-Ferreira M; Grazziotin-Soares D; Langlois-Jacques C; Mercier C; Villeneuve L; Freyer G; Golfier F
    J Clin Oncol; 2020 Sep; 38(27):3129-3137. PubMed ID: 32716740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial.
    You B; Bolze PA; Lotz JP; Massardier J; Gladieff L; Floquet A; Hajri T; Descargues P; Langlois-Jacques C; Bin S; Villeneuve L; Roux A; Alves-Ferreira M; Grazziotin-Soares D; Dherret G; Gerentet C; Rousset P; Freyer G; Golfier F
    Gynecol Oncol; 2023 Jan; 168():62-67. PubMed ID: 36401942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
    Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
    BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
    Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
    Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
    Rattanaburi A; Boonyapipat S; Supasinth Y
    Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
    Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
    Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
    Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Predictive Value of Modeled Human Chorionic Gonadotrophin Residual Production in Low-Risk Gestational Trophoblastic Neoplasia Patients Treated in NRG Oncology/Gynecologic Oncology Group-174 Phase III Trial.
    You B; Deng W; Hénin E; Oza A; Osborne R
    Int J Gynecol Cancer; 2016 Jan; 26(1):208-15. PubMed ID: 26569059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
    Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG
    Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
    Couder F; Massardier J; You B; Abbas F; Hajri T; Lotz JP; Schott AM; Golfier F
    Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
    Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
    J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial.
    Cheng H; Zong L; Kong Y; Wang X; Gu Y; Cang W; Zhao J; Wan X; Yang J; Xiang Y
    Lancet Oncol; 2021 Nov; 22(11):1609-1617. PubMed ID: 34624252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
    Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia.
    Yarandi F; Eftekhar Z; Shojaei H; Kanani S; Sharifi A; Hanjani P
    Int J Gynaecol Obstet; 2008 Oct; 103(1):33-7. PubMed ID: 18632105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia.
    Baptista AM; Belfort P
    Int J Gynaecol Obstet; 2012 Oct; 119(1):35-8. PubMed ID: 22877838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom.
    Taylor F; Short D; Winter MC; Tidy J; Savage PM; Sarwar N; Hancock BW; Seckl MJ; Coleman RE
    Gynecol Oncol; 2015 Feb; 136(2):258-63. PubMed ID: 25542400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy.
    Roberts JP; Lurain JR
    Am J Obstet Gynecol; 1996 Jun; 174(6):1917-23; discussion 1923-4. PubMed ID: 8678159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors related to treatment outcomes in low-risk gestational neoplasia.
    Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
    Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pulsed actinomycin D versus 5-day methotrexate for the treatment of low-risk gestational trophoblastic disease.
    Mousavi A; Cheraghi F; Yarandi F; Gilani MM; Shojaei H
    Int J Gynaecol Obstet; 2012 Jan; 116(1):39-42. PubMed ID: 21996593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.